Modulation of cognitive and emotional processing by cannabidiol: The role of the anterior cingulate cortex

Frontiers in Human Neuroscience

Volumn , Issue APR 2013, 2013, Pages

  Kowal, Mikael A ^a   Hazekamp, Arno ^b   Colzato, Lorenza S ^a   van Steenbergen, Henk ^a   Hommel, Bernhard ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bedrocan BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; ENDOCANNABINOID; TETRAHYDROCANNABINOL;

AFFECT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; CNR1 GENE; COGNITION; COMT GENE; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; EMOTION; GENETIC PREDISPOSITION; HUMAN; NONHUMAN;

EID: 84933670374     PISSN: 16625161     EISSN: 16625161     Source Type: Journal    
DOI: 10.3389/fnhum.2013.00147     Document Type: Article

References (46)

1. Bar-Haim, Y., Lamy, D., Pergamin, L., Bakermans-Kranenburg, M. J., and van Ijzendoorn, M. H. (2007). Threat-related attentional bias in anxious and nonanxious individuals: A meta-analytic study. Psych. Bulletin 133, 1-24.
2. Beng-Choon, H., Wassink, T. H., Ziebell, S., and Andreasen, N. C. (2011). Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizo. Res. 128, 66-75.
3. Bergamaschi, M. M., Quieroz, R. H. C., Chagas, M. H. N., de Oliviera, D.C. G., Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A. E., Martin-Santos, R., Hallak, J. E. C., Zuardi, A. W., and Crippa, J. A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharm. 36, 1219-1226.
4. Bhattacharyya, S., Crippa, J. A., Allen, P., Martin-Santos, R., Borgwardt, S., Fusar-Poli, P., Rubia, K., Kambeitz, J., O'Carroll, C., Seal, M. L., Giampietro, V., Brammer, M., Zuardi, A. W., Atakan, Z., and McGuire, P. K. (2012). Induction of psychosis by delta-9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psych. 69, 27-36.
5. Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O'Carroll, C., Allen, P., Seal, M. L., Fletcher, P. C., Crippa, J. A., Giampietro, V., Mechelli, A., Atakan, Z., and McGuire, P. K. (2009). Modulation of mediotemporal and ventrostriatal function in humans by delta-9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch. Gen. Psych. 66, 442-451.
6. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O'Carroll, C., Seal, M., Allen, P., Mehta, M. A., Stone, J. M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R. M., Zuardi, A. W., Crippa, J. A., Atakan, Z., and McGuire, P. K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharm. 35, 764-774.
7. Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., Rubia, K., and McGuire, P. K. (2008). Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biol. Psych. 64, 966-973.
8. Botvinick, M. M., Braver, T. S., Barch, D. M., Carter, C. S., Cohen, J. D. (2001). Conflict monitoring and cognitive control. Psych. Rev. 108, 624-652.
9. Bush, G., Luu, P., and Posner, M. I. (2000). Cognitive and emotional influences in anterior cingulate cortex. Trends in Cog. Sci. 4, 215-222.
10. Bush, G., Whalen, P. J., Rosen, B. R., Jenike, M. A., McInerney, S. C., and Rauch, S. L. (1998). The counting Stroop: an interference task specialized for functional neuroimaging: validation study with functional MRI. Hum. Brain Map. 6, 270-282.
11. Campos, A. C., and Guimarães, F. S. (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharm. 199, 223-230.
12. Carter, C. S., Mintun, M., and Cohen, J. D. (1995). Interference and facilitation effects during selective attention: an H215O PET study of Stroop task performance. Neuroimage 2, 264-272.
13. Casey, B. J., Trainor, R. J., Orendi, J. L., Schubert, A. B., Nystrom, L. E., Giedd, J. N., Castellanos, F. X., Haxby, J. V., Noll, D. C., Cohen, J. D., Forman, S. D., Dahl, R. E., and Rapoport, J. L. (1997). A developmental functional MRI study of prefrontal activation during performance of a go-no-go task. J. Cog. Neurosci. 9, 835-847.
14. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., Simoes, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Filho, A. S., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. of Psychopharm. 25, 121-130.
15. Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., and Busatto, G. F. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharm. 29, 417-426.
16. Colzato, L. S., Waszak F., Nieuwenhuis, S., Posthuma, D., and Hommel, B. (2010). The flexible mind is associated with the catechol-O-methyltransferase (COMT) Val 158 Met polymorphism: evidence for a role of dopamine in the control of task-switching. Neuropsych. 48, 2764-2768.
17. D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., and Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharm. 29, 1558-1572.
18. Fattore, L., Melis, M., Fadda, P., Pistis, M., Fratta, W. (2010). The endocannabinoid system and nondrug rewarding behaviours. Exp. Neurol. 224, 23-36.
19. Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M., O'Carroll, C., Atakan, Z., Zuardi, A. W., and McGuire, P. K. (2010). Modulation of effective connectivity during emotional processing by delta-9-tetrahydrocannabinol and cannabidiol. Internation. J. Neuropsychopharm. 13, 421-432.
20. Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O'Carrol, C., Atakan, Z., Zuardi, A. W., and McGuire, P. K. (2009). Distinct effects of delta-9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psych. 66, 95-105.
21. Gaoni, Y., and Mechoulam R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J. Amer. Chem. Soc. 86, 1646-1647.
22. Gomes, F. V., Resstel, L. B. M., and Guimarães, F. S. (2011). The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharm. 213, 465-473.
23. Hallak, J. E. C., Machado-de-Sousa, J. P., Crippa, J. A., Sanches, R. F., Trzesniak, C., Chaves, C., Bernardo, S. A., Regalo, S. C., and Zuardi, A. W. (2009). Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev. Bras. Psiquiatr. 32, 56-61.
24. Hardwick, S., and King, L. A. (2008). Home office cannabis potency study. Home Office Scien. Develop. Branch.
25. Hazekamp, A., Ruhaak, R., Zuurman, L., van Gerven, J., and Verpoorte, R. (2006). Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. J. Pharm. Sci. 95, 1308-1317.
26. Holroyd, C. B., and Coles, M. G. H. (2002). The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity. Psych. Rev. 109, 679-709.
27. Kawashima, R., Satoh, K., Itoh, H., Ono, S., Furumoto, S., Gotoh, R., Koyoma, M., Yoshioka, S., Takahashi, T., Takahashi, K., Yanagisawa, T., and Fukuda, H. (1996). Functional anatomy of go/no-go discrimination and response selection: a PET study in man. Brain Res. 728, 79-89.
28. Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., and Henquet, C. (2010). Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizo. Research 121, 107-117.
29. Marco, E. M., García-Gutiérrez, M. S., Bermúdez-Silva, F. J., Moreira, F. A., Guimarães, F., Manzanares, J., and Viveros, M. P. (2011). Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front. Behav. Neurosci. 5:63. doi: 10.3389/fnbeh.2011.00063.
30. Mechoulam, R., Parker, L. A., and Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharm. 42. 11-19.
31. Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
32. Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., Wingham, G., Lewis, S., and Curran, H. V. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psych. Med. 42, 391-400.
33. Morgan, C. J. A., Schafer, G., Freeman, T. P., and Curran, H. V. (2010). Impact of cannabidiol on the acute memory and psychomimetic effects of smoked cannabis: naturalistic study. Br. J. Psych. 197, 285-290.
34. Pardo, J. V., Pardo, P., Janer, K. W., and Raichle, M. E. (1990). The anterior cingulate cortex mediates processing selection in the Stroop attentional conflict paradigm. Proc. Nat. Acad. Sci. 87, 256-259.
35. Paus, T. (2001). Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nature Rev. Neurosci. 2, 417-424.
36. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin. Br. J. Pharm. 153, 199-215.
37. Schier, A. R. M., Ribeiro, N. P. O., Silva, A. C. O., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., and Zuardi, A. W. (2012). Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev. Bras. Psiquiatr. 34, 104-117.
38. Schoedel, K. A., and Harrison, S. J. (2012). Subjective and physiological effects of oromucosal sprays containing cannabinoids (Nabiximols): potentials and limitations for psychosis research. Curr. Pharm. Des. 18, 5008-5014.
39. Schubart, C. D., Sommer, I. E. C., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., and Boks, M. P. M. (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizo. Research 130, 216-221.
40. Spronk, D., Dumont, G. J. H., Verkes, R. J., and de Bruijn, E. R. A. (2011). Acute effects of delta-9-tetrahydrocannabinol on performance monitoring in healthy volunteers. Fron. Beh. Neurosci. 5, 1-11 (59).
41. Stadelman, A. M., Juckel, G., Arning, L., Gallinat, J., Epplen, J. T., and Roser, P. (2011). Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory eventrelated P300 potential. Neurosci. Letters 496, 60-64.
42. Zanelati, T. V., Biojone, C., Moreira, F. A., Guimarães, F. S. (2010). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharm 159, 122-128. bph-521 122.128
43. Zuardi, A. W., Cosme, R. A., Graeff, F. G., and Guimaraes F. S. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharm. 7, 82-88.
44. Zuardi, A. W., Crippa, J. A., Hallak, J. E. C., Pinto, J. P, Chagas, M. H. N., Rodriguez, G. G. R., Dursun, S. M., and Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharm. 23, 979-983.
45. Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., and Crippa, J. A. S. (2006). Cannabidiol monotherapy for treatmentresistant schizophrenia. J. Psychopharm. 20, 683-686.
46. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharm. 76, 245-250.